GI Windows Surgical wins FDA clearance for gastric anastomosis expansion

GI Windows Surgical said Oct. 29 that the FDA cleared an expanded gastric indication for its Flexagon Plus OTOLoc System, extending use to stomach-to-small-intestine connections including gastrojejunostomy. The move broadens the company’s magnetic compression platform into procedures where immediate lumen creation and standardized healing could matter most.

Why it matters: - The FDA clearance expands the potential use of GI Windows Surgical’s magnetic compression anastomosis platform into more complex gastrointestinal surgeries. - The new indication covers connections between the stomach and small intestine, including gastrojejunostomy, a step that can affect procedure consistency, healing and complications. - GI Windows Surgical says the platform is the only magnetic anastomosis technology worldwide that creates an immediate lumen at the time of surgery. - Standard of care requires immediate luminal patency when the anastomosis is created.

What happened: - GI Windows Surgical announced on Oct. 29 that the U.S. Food and Drug Administration cleared an expanded gastric indication for the Flexagon Plus OTOLoc System. - The company is based in Canton, Massachusetts. - The clearance extends the platform to stomach-to-small-intestine connections, including gastrojejunostomy. - The company said the clearance marks a significant expansion of the platform’s clinical application.

The details: - Gastrojejunostomy creation is a technically demanding and clinically consequential step in gastrointestinal surgery. - The Flexagon Plus OTOLoc platform combines self-forming magnets with immediate-lumen technology. - GI Windows Surgical said the technology enables surgeons to use magnetic compression anastomosis in standard-of-care procedures such as Roux-en-Y gastric bypass. - Brian Tinkham, chief executive officer of GI Windows Surgical, called the clearance a defining milestone and said the expansion can make a more meaningful difference for surgeons and patients. - Erik B. Wilson, MD, chief medical officer, said the company’s multicenter, 85-patient trial is part of the clinical work supporting the technology. - Wilson said the company sees an opportunity to standardize anastomosis creation and support reliable healing, with potential for fewer GJ-related complications. - Carlos Galvani, MD, FACS, FASMBS, professor and chief of general surgery at LSU Health New Orleans, said extending the technology to gastrojejunostomy creates an opportunity to pursue greater consistency and efficiency, with reliable healing and better patient outcomes as the goal.

Between the lines: - The clearance suggests GI Windows Surgical is moving from a narrower application toward a broader surgical platform strategy. - The focus on immediate lumen and standardization points to a pitch aimed at both clinical reliability and workflow efficiency. - The company’s messaging frames the clearance as an entry point into procedures where small changes in technique can have outsized effects on recovery and complications.

What's next: - GI Windows Surgical will likely use the expanded indication to build adoption in additional gastrointestinal procedures. - The company said its longer-term goal is to improve procedural efficiency, drive standardization and advance patient outcomes. - More information is available in the company’s announcement.

The bottom line: - The FDA clearance gives GI Windows Surgical a wider commercial and clinical runway for its magnetic anastomosis platform, with gastrojejunostomy now in scope.